#LEAP-012
LightNews LightNews
lorenzarimassa.bsky.social
Josep Llovet presents long-term OS results of #LEAP-012 in #intermediate stage #HCC at #ESMO26 #ESMOAmbassadors @myesmo.bsky.social
October 26, 2026 at 4:45 PM
oncoalert.bsky.social
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Phase 3 LEAP-012 Study of Lenvatinib + Pembrolizumab vs Dual Placebo With Transarterial Chemoembolization (TACE) for Unresectable Non-Metastatic Hepatocellular Carcinoma: Long-Term OS Results
October 22, 2026 at 12:00 PM
wizybit.bsky.social
2/5 Three Phase 3 programs terminated in days—a melanoma adjuvant study (KEYVIBE-010), a lung-cancer combination trial (KEYVIBE-007), and a hepatocellular carcinoma cohort (LEAP-012)—alongside two Phase 2 oncology halts and one healthy-volunteer withdrawal for V540A.
September 15, 2026 at 1:25 PM
wizybit.bsky.social
1/5 💊 $MRK Merck Sharp & Dohme flagged a cluster of biotech setbacks: InsiderWatch's trial-status tracker surfaced terminations across three Phase 3 programs—KEYVIBE-007 (metastatic non-small cell lung cancer), KEYVIBE-010 (adjuvant melanoma), and LEAP-012 (hepatocellular carcinoma)—all in
Read the full story
MRK's Pipeline Crisis: Three Phase 3 Trials Terminated in Days InsiderWatch | insider.wizybit.com
insider.wizybit.com
September 14, 2026 at 1:25 PM
wizybit.bsky.social
2/7 The LEAP-012 study in patients with incurable non-metastatic HCC represents a setback for the immuno-oncology combination approach Merck has pursued aggressively across multiple indications.
September 4, 2026 at 1:25 PM
oncoalert.bsky.social
LEAP 012 Update/ Source MERCK
Merck and Eisai announced results from the Phase 3 LEAP-012 trial evaluating the combination of pembrolizumab and lenvatinib TACE in unresectable, non-metastatic hepatocellular carcinoma.

did not achieve statistical significance for OS

www.merck.com/news/merck-a...
October 29, 2025 at 12:07 PM
simulatedannealing.bsky.social
LEAP-012

Grade 3+ treatment-related adverse events occurred in 169 (71%) of 237 participants in the lenvatinib plus pembrolizumab group and in 76 (32%) of 241 in the placebo group

TACE is a very poor toxic treatment; why is anybody still doing this in 2025?

www.thelancet.com/journals/lan...
www.thelancet.com
January 10, 2025 at 3:26 AM
simulatedannealing.bsky.social
It’s sad to see TACE being used as local control backbone in unresectable HCC in 2025 #radonc

www.sciencedirect.com/science/arti...
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-...
Transarterial chemoembolisation (TACE) is standard care for unresectable, non-metastatic hepatocellular carcinoma. We aimed to evaluate the addition o…
www.sciencedirect.com
January 10, 2025 at 2:35 AM
tamedoncol.bsky.social
ICI combos are reshaping hepatocellular carcinoma care. Phase III trials (IMbrave050, EMERALD-1, LEAP-012) show promise in resectable & embolization-eligible settings, but survival benefits remain unclear. More research is needed. #CancerResearch

🔗 Read the article: buff.ly/kbZ7ewQ
December 10, 2025 at 8:15 AM
oncodaily.bsky.social
LEAP-012: Pembrolizumab Plus Lenvatinib with Transarterial Chemoembolization in Unresectable, Non-Metastatic HCC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LEAP-012 #HCC
November 2, 2025 at 9:41 PM
robbrierley.bsky.social
New research - TACE combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

www.thelancet.com/journals/lan...

@thelancet.bsky.social #MedSky #OncSky #LiverSky
January 9, 2025 at 8:09 AM
robbrierley.bsky.social
#TLM24 late breakers session kicks off with Josep Llovet presenting an interim analysis of the phase 3 LEAP-012 trial of pembrolizumab plus TACE for intermediate stage hepatocellular carcinoma #OncSky #LiverSky
November 18, 2024 at 10:12 PM
longtail-news.bsky.social
Feed: "Clinical Trials Arena"
By: sdebbarma on Thursday, October 30, 2025
MSD and Eisai to end Phase III LEAP-012 trial for unresectable HCC
MSD and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic HCC as Keytruda plus Lenvima, along with TACE, failed to achieve statistical significance for OS.
www.clinicaltrialsarena.com
October 31, 2025 at 6:46 AM
epsteinweb.bsky.social
Parts 1-3/3 — EFTA01312884.jpg
#epsteinweb #efta01312884
https://epsteinweb.org
EFTA01312877 | EFTA01312884 Invoice Number: 1.810.82230 May 31.2004 Invo:ce Dale: Accounl Number Page: 8 of 8 FedEx Ground Reference Chart SERVICE CODES FedEx Ground 015 016 012 019 00 021 131 136 132 140 408 409 410 412 415 416 417 419 419 420 421 422 423 429 CO 431 432 433 438 440 441 442 443 444 445 445 900 .49-6,00. Pieced MO.P.m*, E000. Prepay Prowl AsnaP00. Cdlsa coma 3rd Parry. Saudi Lumen Pismo Law Prepaid. Relufn leisioder calm Lao Prepad. anon Innnef Pined Label 3rd Pang. Return Linger *Mee Lat:el Pritvanked Girds COO. Peeped Currency COO. Preyed An:41430. COD. Provo/3 AutoP013. ECCO. Prawn Aux4,00. Guarantee! Finds COD. Prepaid Aux4,00. Canatty CCD. Prepaid 3.91Perry Mpg 3rd Parry Mop. AuloPCO 3,41Parry 94Ing. COO 3rd Pay Nang. 0earanteedRods CCO 3M Pang &law Canny COD allleseipam allleacipat6 AutoPCO 3rd Pang Botng. ECOO 3rd Pang Mr,. AuloPCO. COO 3rd Parry Oar,. AuloPCO. ECOD 3rd Parry Mop. Au1oPCO. etnency COD 3M Pang Slew PaioPCO. &aranlood Funde. COD Prep/id. Craktani003 Funds. ECCO Prepaid. Miry. ECCO Pea044 Gatramecn Funds. ECCO. AatoP013 Pree,v8 Curiercy. ECOO. AbeePOD 3rd Pant rg. Otaarantec4 rifle. MD 3rd Pant r0. (Virg. ECOD 3rd Pant Bilr9.49aranteedlwde. ECOD.AtnaPCO 3m Pane 8.11-4. CitrerCr. ECOD.AutoPCO Coasolaat40 Nona 3M Pay. Iwo FedEx International Ground 022 023 026 027 028 135 141 478 479 480 465 486 487 488 4.89 490 491 492 493 An:POO. Prepad CCO.P09944 Prerowd catoa cam 3M Pay. RUM Maned" Perned aatei Prepaid.Returil krasurpOrPdroid Libel Garanle40 Funds. 000.Pinged Currency. COD.Propod Pentad. AtnaP00. 000 Prerosd.Marne. Gummed Fends. COO Pewit /64014CO. Dismay COD 3a3 Pang Bane Id Pang Bile"..444POD 3a3 Paw Slay. COO 3,0 Peary 44.4.0eaaranteedFuns COO are Parry Mr4.(anancy COD Em Annum EMInornm AtnyPOD ZONE DEFINITIONS FEDEX HOME DELIVERY SERVICE CODES 900 804 800 610 814 SIB 820 824 628 830 834 636 842 847 848 850 651 652 4153 1654 855 856 857 659 459 860 869 670 871 872 873 876 875 876 877 878 879 ta4PCO. Payed Peron Srome. P•coaml E•enrg. 420oPCO. Pmpan1 Ena.n/4. Pond Ewan,. Sogruguce.Prepaid Date Conain.PuloPCO. Promo Dale Conan.Prepaid Ode Oman. Strome. Amu, ApparremOelvery. Ao1oPCO. P•coaml Aroarrem °elven. Pined 3rd Pat,. Ream Inman Pnnes Lena Peeped. Return ilieareir PMyn latel 343 Ps7/. FeY1.411AWlegre Mine La.'. Peeped. Winn ilieareir Oriel> LaPil 343 Parry an° 3rd Parry &Ina AuloP00 3rd Party Sing. Spreirtire Jro Parry Shy. 6•6-4,9 3,0 Parry Slog. Ewa, 4,4000 343 Pay Blew Evarina Sgnando 343 Pan, BIN. Dare Peden 3rd Parry Blew Dace Coma. 444oPCO 33,0 Pant, &Ina. Dee Cenao.Sinilioe 14ponirrenl WIMP 31d Parry are Pat, atm. anyoninsni Munn. 044,POD III Reopen, III Reopen. AtnaPCO EMI Reelpiall. Sip1.1620 OilReelpiall. &pone 811R4C10401. 600.19.1.410PCO e 041Reopen,. En4r9.34-pahre 041Reopen,.Dal Ode Oman 041Reopen,. Gale Celan. AvroPC4) 811Reopen,. Oale Cenan.Strare eel Reapeoi. Appoirentom Dawn Bit Roapent Amoinwom Deka,. /440PCO 0.1 Word Say oo rm. Cared 24 Mama Swot 40 coG129:69 llgt1 74 Grand Serve, 45 COMdu:us ,wts 9 Swim 13 Kw.. KO Santo loPuitrielitrio 14 Sertileel0Oitu 17 Serrieel0 Mairta 22 SWOP) *MP Araii.9 23 Stmce 1.0.3A4t3e 23 Senwe ecnualuke 515 54 Siewe le Ceti,* 92196 Serme ecen moan, 0*i-rep OTHER CHARGE CODE DEFINITIONS 111 121 1311 4) 61 ri 81 91 60) I) .13) 13) 14) IS) IS) 20) 21) 22) 23) 24) 23) 26) 2» 26) 29) 30) 35) 3n 36) 39) 40) 141) NA 144) 145) 146) 147) 144) 149) ISO) 151) 152) 153) 154) 155) COO. teole:t m Oetatqo A.O.0. lacantra 'bonen el DdiGerr) cos Tog 0491,113 a 84- Ccatnod LONGDedered Pau* Ackeens Convene Hazardaus Material Avdrne9c Proof el Dewey A0lions Nyberg °True Ulm Somas Fee Oaso9Mo 150191. ElearaliC CO O.. 24 Meta ElearaliC Coo 48 lies. FeeEx Groan, Rectdmbal FeeEx Ground Reeideribel • litfl Reltains KWOan Transmoson Fee FeeEx Sinks, Mane Delany Podlx 09.61 Sedan Wale Doosy FodEx 480.1694911 Wale Dw.oy FodEx Evening Harris Oeleary PodEx Mono DaletsyRatiSNIIIII FodEx Ilene WennRetclen1.0 • Airs Cash 0.00.Oagv Cam C 00 lir Oentity eta,' Cann C OD Ewa Cceereco, C Peatdor Deasy makentqa h. FedEx Minn Nave.,Facto Fuel Sun:Parge °sum a 108' Comtinod Lens, any Gem Omura s let m leap. Orwpze s lv Comtme4 Lerr en! Girth Surgtmernal Overage Package *age Cane* Goods I Sracee lax -CST Canada Harininided Safes Tax .11ST Canada Mabee Solis Tax OST Nel Rearm Credo Caro Orin,&mango Consolesna Nen Payng Consokbeed Seer. Package 2214.2x648 Conso1Osea Rearm Pec144e 4444 448412 Consoldsea Rit,rra Package 6x6410.6110.16 COMOICIar.“ Parra Parke/yr8910612 . 10913.,6 Comoklated Sawn Parka°. FI CIIWO COMOIrliaid Pawn Osertitri Paster,. Charge Relttns Kroger Canada., Orcot847Irene) OVrje unanonfoOnfrtare s 165' emboli,LO.$ I OS CONFIDENTIAL SONY_GM_00339249 EFTA 00211944 EFTA01312884
February 17, 2026 at 9:24 AM
cor2ed.com
📢 Key insights from the Phase 3 LEAP-012 study

➡️Lenvatinib + pembrolizumab + TACE versus double placebo + TACE for patients with intermediate #HCC

w/Prof. @arndtvogel.bsky.social

cor2ed.com/hcc-connect/...

This Independent programme has been sponsored by Eisai Europe Limited ("Eisai")

#MedEd
LEAP-012 publication snapshot | COR2ED
Discover insights from the Phase 3 LEAP-012 study evaluating lenvatinib + pembrolizumab + TACE versus double placebo + TACE for patients with intermediate
cor2ed.com
March 25, 2025 at 9:08 AM
thenextleap.is
This is the nuanced debate about defence that we need to be having right now. Hetti Barkworth-Nanton, CEO of the Ministry of Defence's Ploughshare Innovations and chair of Refuge, joins the podcast to discuss why defence innovation is about protecting the vulnerable thenextleap.is/episode/012-...
The Next Leap » Hetti Barkworth-Nanton: Defence innovation is about protecting the vulnerable
Hetti Barkworth-Nanton, CEO of Ploughshare Innovations and chair of Refuge, explores how security innovation and social impact can coexist.
thenextleap.is
March 24, 2026 at 3:15 PM
chanface.bsky.social
Final Haul!

My Europe trip has sadly come to an end.

Guess all the places.

(I tried to organize it semi-geographically)
Assortment of 12 transit cards. Leap 10514 01507 0425 Uimhir/Number TFI Leap visitor TRANSPOR IRELAND 80221 60245 U125 ลกdante navegante ML3561901621 ricket No 62 .00 610139323 Vallo unti13:33 07 May 26 for Adult Luas onl y roll Busaras CENTRAL Single LynS oyster Transport for London barik ctb ** MADRID (2 1心◎ Tu ritmo, tu transporte Tarjeta MULTI Teléfono: 012 / crim.es 04347142F72290 MB1-548384 อล Gedig op Enkele reis Schiphol Airport Amsterdam* 24-04-2026 In- in ultrecten vemiere Creein and out required Pris € 5,50 Toeslag € 1,60 CIV euskotren 231CT1 HOLI Your travel solution + ren & tú TMB Transports webecom + renfe N.° Cliente / Bezero zenbakia:
May 8, 2026 at 7:58 PM
onclive.bsky.social
LEAP-012 Trial of Pembrolizumab/Lenvatinib/TACE to Close Following Missed OS End Point in Unresectable HCC #oncology www.onclive.com/view/leap-01...
LEAP-012 Trial of Pembrolizumab/Lenvatinib/TACE to Close Following Missed OS End Point in Unresectable HCC | OncLive
TACE plus pembrolizumab and lenvatinib did not improve OS vs TACE alone in patients with unresectable HCC.
www.onclive.com
October 29, 2025 at 4:18 PM
onclive.bsky.social
Combination Regimens Make Their Mark in Frontline HCC @danengle.bsky.social #ESMO24 #oncology
www.onclive.com/view/combina...
Combination Regimens Make Their Mark in Frontline HCC
In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.
www.onclive.com
December 24, 2024 at 1:07 PM
medical-research.bsky.social
🚨 New hope for liver cancer patients! 🧪 The LEAP-012 trial shows that adding lenvatinib + pembrolizumab to TACE significantly extends progression-free survival in intermediate-stage hepatocellular carcinoma HCC.

📚💙 #LiverCancer #MedicalBreakthrough #medschool #medsky #medical #research #cancer
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
TACE plus lenvatinib plus pembrolizumab showed significant, clinically meaningful improvement in progression-free survival in patients with unresectable, non-metastatic hepatocellular carcinoma compared with TACE plus placebo. The numerical improvement in overall survival is encouraging, but longer follow-up is necessary.
www.thelancet.com
January 11, 2025 at 2:50 AM
postnatodepression.bsky.social
"A dream, after having supped."
Charles Heaphy, 1850s?
After squatting near Motueka, Heaphy surveyed much of New Zealand to determine how much was suitable for organised settlement. He wrote off the whole of the West Coast in disgust & moved to Nelson.
Ref A-145-012
National Library of New Zealand.
Shows eleven skeletons engaged in various activities. Two hang from gallows, two are engaged in a game of leap-frog, one dances with a parasol, one sits with a bottle and wineglass. Two are dancing balletically and two are seated on a coffin. One has fallen on his front and broken into pieces.
September 14, 2024 at 4:35 AM
thejaymo.net
📬 Issue #012 of Start Select Reset Zine is out now!

🤺 Shadow Boxing – Battling imaginary critics online
✍️ Long Form Leap – Writing past 8-10k words

🔥 Next 10 subscribers get Issue #11, my solo game Quiet Quests!

📖 Join the mailing list today!
Start Select Reset Zine #012 | Shadow Boxing x Long Form Leap
This issue is a double feature, exploring two intertwined challenges: Shadow Boxing and my move to long form essay writing.
thejaymo.net
January 20, 2025 at 4:31 PM
oncoassist.bsky.social
🚨New in #Oncology!

🧬 Phase 3 LEAP-012 Trial Update!

Merck & Eisai share results from the Phase 3 LEAP-012 study evaluating KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib) in combination with TACE for patients with unresectable, non-metastatic hepatocellular carcinoma (HCC).
October 30, 2025 at 12:30 PM
flarestart.bsky.social
Docker Containerization: The Leap from Bare Metal to Containers
via Dev.to DevOps

https://flarestart.com/article/docker-containerization-the-leap-from-bare-metal-to-containers-20260218
#DevNews #DevOps #Tutorial
Docker Containerization: The Leap from Bare Metal to Containers
Docker Containerization — The Leap from Bare Metal to Containers Joe's AI Manager Log #012 Why Containerize With agent count growing past 20, managing OpenClaw processes on T440 became chaotic....
flarestart.com
February 18, 2026 at 11:39 AM
dufourjf.bsky.social
Prof Kudo explains the results of the LEAP-012 trial which found benefits in combining TACE sessions with lenvatinib and pembrolizumab for unresectable hepatocellular carcinoma
shorturl.at/3RXFv
LEAP-012 Trial – A New Standard of Care for Unresectable, Non-Metastatic HCC? – Overcome Liver CancerGroup 6Group 6
shorturl.at
February 19, 2025 at 6:59 PM